Personalized Nanotechnology for Ovarian Cancer
Nanotechnology-based personalized treatment of metastatic ovarian cancer
This project aims to create a new way to deliver chemotherapy for gynecologic cancers, tailoring it to each patient's unique tumor.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rutgers Biomedical and Health Sciences NIH-funded |
| Lab location | 1 site (Newark, UNITED STATES) |
| Project ID | NIH-11083626 on NIH RePORTER |
What this research studies
We are working to develop a personalized chemotherapy approach for ovarian cancer, which is the most deadly type of gynecological cancer. This method will use tiny nanocarriers to deliver anti-cancer drugs directly to tumor cells, based on the specific genetic makeup of a patient's tumor. By analyzing samples from a patient's tumor, we can identify unique targets and choose the most effective drugs. This tailored approach is designed to overcome drug resistance and improve treatment outcomes.
Who could benefit from this research
Good fit: Patients with metastatic ovarian cancer who are undergoing tumor debulking surgery may be ideal candidates for future clinical trials stemming from this work.
Not a fit: Patients with early-stage gynecologic cancers or those not suitable for chemotherapy may not directly benefit from this specific personalized drug delivery approach.
Why it matters
Potential benefit: If successful, this approach could lead to more effective and personalized chemotherapy options for women with advanced ovarian and other gynecologic cancers, potentially improving survival and reducing side effects.
How similar studies have performed: While personalized medicine and nanotechnology in cancer treatment are active areas of research, this specific combination of genetic profiling with complex nanocarrier-based targeted delivery for gynecologic cancers represents a novel approach.
Where this research is happening
Newark, UNITED STATES
- Rutgers Biomedical and Health Sciences — Newark, United States (Active)
Researchers
- Principal investigator: Minko, Tamara — Rutgers Biomedical and Health Sciences
- Study coordinator: Minko, Tamara
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.